Posted by Michael Wonder on 20 Nov 2021
Pfizer's Xeljanz (tofacitinib) receives marketing authorisation in the European Union for the treatment of active ankylosing spondylitis
18 November 2021 - Pfizer announced today that the European Commission has approved Xeljanz (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis who have responded inadequately to conventional therapy.
The approval of Xeljanz for ankylosing spondylitis is based on data from a Phase 3, multi-centre, randomised, double-blind, placebo-controlled trial that evaluated the efficacy and safety of tofacitinib 5 mg twice daily versus placebo in 269 adult patients living with active ankylosing spondylitis.
